MacroGenics reports Q2 EPS (89c), consensus (59c)

Reports Q2 revenue $10.8M, consensus $21.24M…Cash, cash equivalents and marketable securities balance as of June 30 was $140.4M, compared to $229.8M as of December 31, 2023. The June 30 balance did not include the $100M in milestones subsequently received from Incyte (INCY).”We are pleased to have the opportunity to present updated safety and efficacy data from our Phase 2 TAMARACK trial of vobra duo at the upcoming European Society for Medical Oncology ESMO Congress in September,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “In addition, we recently solidified our cash position with the receipt of $100.0 million in milestones, following the positive Phase 3 top-line results from Incyte’s registrational studies of retifanlimab in both anal and lung cancer.”